Clinical Research · eu
Making Surviving Retinal Cells Sensitive to Light: Optogenetic Therapy Shows Limited Visual Improvements in a Ten-Person Trial
Gene therapy paired with special goggles helped some patients with advanced retinitis pigmentosa better perceive light and locate objects. This small trial builds on early findings in a single patient, but the improvements were limited, and the study design was insufficient to establish efficacy.
For someone who has lost nearly all their sight, perceiving an object on a table may be a small step toward reconnecting with their surroundings. A trial of optogenetic therapy in patients with advanced retinitis pigmentosa observed improvements in some participants’ perception of light and simple objects with the aid of special goggles. However, these changes remain far from a clear view of the world and cannot yet be considered proof of efficacy.
GenSight Biologics and the 15-20 National Hospital in Paris announced on October 8 that results from the Phase 1/2 PIONEER trial of GS030 had been published in The New England Journal of Medicine. The study enrolled 10 people, with safety as its primary objective and visual function assessed on an exploratory basis. It builds on the research team’s 2021 proof of concept in a single patient, allowing scientists to examine whether similar visual responses could occur in more patients.
Retinitis pigmentosa is a group of inherited diseases that cause the cells responsible for sensing light to gradually degenerate. GS030 attempts to bypass this damaged step: an intravitreal injection into one eye delivers the gene for a light-sensitive protein to surviving retinal ganglion cells, enabling cells that normally transmit information to respond to light as well. The accompanying goggles use a camera to capture the surroundings and convert changes in the images into light signals that stimulate these cells.
The University of Basel’s account provided two distinct levels of results: 7 of the 10 participants showed increased light sensitivity, with 6 reaching a predefined threshold for clinical significance; the company and the Institute of Molecular and Clinical Ophthalmology Basel focused their reporting on the latter. Among the 8 participants who completed visual behavior testing, 4 improved on some tasks involving detecting, locating, or touching objects, but individual performance varied widely. An improved ability to perceive light does not mean that high-resolution vision has been restored.
Learning how to use these unfamiliar signals may also influence the results. The institute noted that participants who received more training with the goggles tended to perform better at object detection; electroencephalographic recordings in some participants also showed changes consistent with visual signals reaching the brain. These observations provide supporting evidence of visual processing, but the association between the amount of training and performance is insufficient to prove that additional training produces a specific degree of improvement.
The safety findings also need to be read alongside the specific events. According to the University of Basel, most ocular adverse events were mild or moderate, but one temporary blockage of retinal blood flow classified as severe occurred after injection and resolved completely within minutes following intervention. Even if the overall tolerability findings support further research, experience in 10 people is insufficient to rule out less common risks.
The study had no control group and a small sample, making it difficult to distinguish the respective effects of treatment, familiarity with the tests, and other factors. The progress so far lies in identifying the possibility of using surviving nerve cells to transmit limited visual information after severe degeneration of light-sensing cells. Turning these signals into stable, practical everyday vision will require studies better able to validate the findings; GS030 has not yet received marketing authorization.